Introduction
============

Gastric cancer (GC) is the second leading cause of cancer death, with East Asia accounting for more than half of the annual cases[@B1]. Although the incidence of gastric cancer has been declining mainly due to the increased availability of fresh fruit and vegetable and the decreased reliance on salted and preserved food[@B1], in 2011 there were still about 420,000 new cases diagnosed (70% are men and 30% are women) and around 300,000 death due to this disease in China[@B2], [@B3]. Therefore, it is of great importance to find new molecular markers that will help evaluate the prognosis or develop novel therapies for gastric cancer.

Cyclin-dependent kinase 5(CDK5) is aproline-directed serine/threonine kinase discovered and reported by Hellmich in 1992[@B4]. CDK5 has strong homology with the mammalian Cdk2 and yeast cdc2 and is an unusual molecule in the Cyclin-dependent kinases (Cdks) protein family[@B4]. Unlike the other Cdks, CDK5 has no known cell cycle or mitotic function and is not activated by cyclins[@B5]. Instead, CDK5 is activated via association with either of the two obligate CDK5-specific activator proteins, p35 or p39[@B6], [@B7]. Previous studies indicated that CDK5 participates in a variety of pathological and physiological functions including neuronal migration during brain development, synaptic activities in mature neurons and neuronal cell survival and death[@B8]-[@B10]. In neurons, the function of CDK5 as a cell cycle suppressor is independent of its kinase activity, but its nuclear localization via association with p27 (also known as KIP1)[@B11] and p35-mediated full assemble of the E2F1-CDK5 complex are needed[@B12], [@B13]. Recently, CDK5\'s functions beyond the nervous system are emerging and increasing evidence suggested a function of CDK5 in cancer tumorigenesis and progression. For example, CDK5 has been implicated in the regulation of the motility and migration of prostate cancer cell lines[@B14], and modulation of the proliferation of medullary thyroid carcinoma and hepatocellular carcinoma cells[@B15], [@B16]. Furthermore, elevated CDK5 activity has been detected in pancreatic and lung cancers[@B17], [@B18].

The CDK5 interacting protein p27 is a cyclin-dependent kinase inhibitor and has a central role in cell cycle regulation[@B19]. By getting incorporated into the CDK4/6-Cyclin D complex or the CDK2-Cyclin E/A complex, p27 restrains the G1 phase initiation and G1/S transition[@B20], [@B21]. As a critical regulator of cell cycle progression, p27 has been considered to be a tumor-suppressor gene in the conventional view[@B22], [@B23]. In studies on gastric cancers, it has been reported that p27 decreased significantly in relation to tumor progression[@B24]. Some studies have shown that low levels or loss of p27 expression is a significant predictor of reduced survival and tumor progression in ovary[@B25], breast[@B26],colon[@B27], lung[@B28]and liver cancers[@B29], However, in GC controversial roles of p27 have been reported and further research is needed to elucidate its function[@B30]-[@B32].

In our previous work, we have demonstrated that in GC CDK5 down regulation was an independent prognostic factor and the nuclear localization of CDK5 was critical for its tumor suppressor function[@B33]. Given that CDK5 nuclear localization depends on p27 in neurons, we hypothesized the functional correlation between CDK5 and p27 may affect each other\'s prognostic power. In the present study, we examined the expression of CDK5 and p27 in 244 gastric tumor tissues obtained from patients with resected gastric cancer and analyzed their correlation with patient clinicopathologcial features.

Materials and Methods
=====================

Patients and Specimens
----------------------

The study cohort was composed of samples from 244 patients with gastric adenocarcinoma, including 180 men and 64 women (mean age, 59.4 years), who had undergone gastrectomy at the Department of Gastric Surgery, Fujian Medical University Union Hospital, between January 2009 and December 2009. Following surgery, routine chemotherapy was given to patients with advanced disease; no radiation treatment was administered to any of the patients. Eligibility criteria for this study included the following: (1) histologically proven adenocarcinoma, (2) not with other gastric tumors such as gastric stromal tumor, (3) no history of gastrectomy or other malignancy, (4) not received the neoadjuvant chemotherapy (5) availability of complete clinicopathological and survival data. The study was performed with the approval of the ethics committee of Fujian medical union Hospital. Written consent was given by the patients for their information and specimens to be stored in the hospital database and used for research.

Clinicopathological and Survival Data
-------------------------------------

The clinical and pathological data were recorded prospectively for the retrospective analysis. The clinicopathological data for the 244 gastric cancer patients included age, sex, size of primary tumor, location of primary tumor, degree of differentiation, histological type, Lauren\'s classification, Borrmann type, depth of invasion, lymph node metastasis, TNM stage, vessel invasion and distant metastasis. The pathologic stage of the tumor was re-assessed according to the 2010 International Union Against Cancer (UICC) on gastric cancer TNM classification (seventh edition)[@B34]. Overall survival was defined as the time from curative surgery to death or the last clinical follow-up. After surgery, all patients were followed every 3 months in the first 2 years, every 6 months in the next 3 years and every year afterwards or until death. The deadline for follow-up was October 2015. All patients had follow-up records for more than 5 years.

Immunohistochemistry
--------------------

Paraffin blocks that contained sufficient formalin-fixed tumor specimens were serial sectioned at 4μm and mounted on silane-coated slides for immunohistochemistry analysis. The sections were deparaffinized with dimethylbenzene and rehydrated through 100, 100, 95, 85, and 75 % ethanol. Antigen retrieval treatment was done in 0.01 mol/L sodium citrate buffer (autoclaved at 121°C for 2 mins, pH 6.0) and endogenous peroxidase was blocked by incubation in 3% H~2~O~2~ for 10 mins at room temperature. The sections were then washed in PBS and blocked with 10 % goat serum (ZhongShan Biotechnology, China) for 30 mins and incubated with rabbit anti-human CDK5 (sc-173, 1:150 dilution, Santa Cruz Biotechnology, polyclonal) or p27 (ab32034, 1:250 dilution, Abcam, monoclonal) antibody in a humidified chamber at 4°C overnight. Following three additional washes in PBS, the sections were incubated with HRP-conjugated secondary antibody for 30 mins at room temperature. The visualization signal was developed with diaminobenzidine (DAB) solution and all slides were counterstained with 20 % hematoxylin. Finally all slides were dehydrated and mounted on cover slips. For negative controls, the primary antibody diluent was used to replace primary antibody.

Evaluation of Immunostaining Intensity
--------------------------------------

The IHC-stained tissue sections were reviewed under microscope by 2 pathologists who were blinded to the clinical parameters, and scored independently according to the intensity of cellular staining and the proportion of stained tumor cells[@B35]. In cases of discrepancy, we re-evaluate the samples and a consensus score was chosen for evaluation. The criteria for the CDK5 and p27 staining score were different. The CDK5 proteins were immunohistochemically stained yellowish to brown in the cytoplasm and/or nuclei of cancer cells. The expression pattern of CDK5 was all or none in tumor tissues, suggesting the score for the proportion of stained tumor cells was unavailable. The staining intensity was scored as 0 (no staining), 1(weak staining, light yellow), 2 (moderate staining, yellow brown), and 3 (strong staining, brown) (Fig. [1](#F1){ref-type="fig"}A). The CDK5 protein expression was considered low if the score was 1 or less and high if it was 2 or more. Different from CDK5, p27 mainly localized in the nuclei of gastric cancer cells (235 out of 244) and its expression pattern was not either all or none. The criteria for the p27 staining were scored are as follows: the intensity score was counted as the same with CDK5 and the proportion of stained tumor cells was classified as 0 (≤5% positive cells), 1 (6% to 25% positive cells), 2 (26% to 50% positive cells) and 3 (≥51% positive cells) (Fig. [1](#F1){ref-type="fig"}B). The p27 protein expression was considered low if the total score (distribution score + intensity score) was 3 or less and high if it was 4 or more. The percentage of positive cells was calculated by counting the number of positive-staining cells showing immune reactivity on the cell nuclei in 10 representative high power fields.

Statistical and Survival Analysis
---------------------------------

The IBM SPSS (SPSS, Chicago, IL) was used for all statistical analyses. The χ2 test (or the Fisher exact test) was used to analyze categorical data. Univariate survival analysis was performed using the Kaplan-Meier method, and the significance of difference between groups was analyzed using the log-rank test. The Cox proportional hazards regression model was used for multivariate survival analysis, with adjustments for variables that might be significant prognostic factors according to the univariate analysis. All P values were 2-sided and statistical significance was determined at *P* \< 0.05.

Results
=======

Expression Status of CDK5 and p27 in Gastric Cancer
---------------------------------------------------

First, we examined the CDK5 and p27 protein expression in tumor tissues from 244 gastric cancer patients using immunohistochemistry. No correlation was observed between CDK5 and p27 protein expression (R=0.173, p\<0.05). The expression of CDK5 protein was scored as low in 93(38.11%) samples and high in 151 (61.89%) samples. In addition, CDK5 expression was observed in the cytoplasm and nuclei of gastric cancer cells, but not in the smooth muscle, vessel or stromal fibroblast cells (Fig. [1](#F1){ref-type="fig"}A). The expression of p27 protein was scored as low in 157(64.34%) samples and high in 87(35.66%) samples. Different from CDK5, p27 localized in the nuclei of gastric cancer cells(Fig. [1](#F1){ref-type="fig"}B). Based on the combined expression of CDK5 and p27, we classified the patients into four subtypes: CDK5 Low/p27 Low (n = 69), CDK5 High/p27 Low (n =88), CDK5 Low/p27 High (n = 24) and CDK5 High/p27 High (n =63).

Correlation between CDK5 and p27 Expression and Clinicopathological Variables
-----------------------------------------------------------------------------

Second, the correlation between the expression of CDK5 and p27 and the clinicopathological features are analyzed (Table [1](#T1){ref-type="table"}). The expression of CDK5 was significantly related to sex (*P*=0.034) and Lauren\'s classification (*P*=0.013). Low expression of CDK5 was observed more frequently in female patients or patients with diffuse type. The expression of p27 was significantly related to sex (*P*=0.012), differentiation (*P*=0.003), TNM stage (*P*=0.013) and lymph node metastasis (*P*=0.001). Female patients or patients with high TNM stage (stages III and IV), poor differentiation, lymph node metastasis were more likely to possess lower expression of p27 (Table [1](#T1){ref-type="table"}). The correlation between simultaneous low CDK5 and p27 expression and the clinicopathological features were also analyzed and the CDK5 Low/p27 Low expression was more often detected in female patients (*P* = 0.026), and patients with diffuse type (*P* = 0.027) and lymph node metastasis (*P*= 0.010) (Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

Prognostic Value of CDK5 and p27 Expression
-------------------------------------------

To elucidate the prognostic value of CDK5 and p27 expression, univariate Kaplan-Meier and multivariate Cox regression analyses were employed. Univariate analysis revealed that the overall survival was significantly associated with size and location of primary tumor, Borrmonn type, degree of differentiation, depth of invasion, lymph node metastasis, TNM stage, vessel invasion, distant metastasis, CDK5 expression and p27 expression, but not with sex, age at surgery, histological type, and Lauren\'s classification (Table [2](#T2){ref-type="table"}) .

The 3- and 5-year cumulative survival rates were 50.5% and 40.6% for patients with low CDK5 expression, and 62.7% and 52.7% for those with high CDK5 expression. The mean survival time for patients with low and high expression of CDK5 were 40 and 75 months respectively. Clearly, gastric cancer patients with low expression of CDK5 had a poorer prognosis than those with high CDK5 expression (P\<0.05) (Fig.[2](#F2){ref-type="fig"}A). The 3- and 5-year cumulative survival rates were 53.2% and 42.2% for gastric cancer patients with low expression of p27, and 66.7% and 58.6% for those with high p27 expression. The mean survival time for patients with low and high expression of p27 in gastric cancer were 45.8 and 55.7 months respectively, suggesting a shorter overall survival for gastric patients with low expression of p27 (P \< 0.05) (Fig. [2](#F2){ref-type="fig"}B).

Next, we further evaluated the prognostic value of the combined CDK5 Low/p27 Low expression. The CDK5 Low/p27 Low patients displayed poorer survival in comparison with the rest of the patients in Kaplan-Meier analysis (Fig. [3](#F3){ref-type="fig"}A). The 3- and 5-year cumulative survival rates were 46.4% and 37.3%, for the CDK5 Low/p27 Low patient group respectively, and 62.7% and 52.3% for the CDK5 High and /or p27 High patient groups respectively. The mean survival time was 40.3 months for patients with CDK5 Low/p27 Low, and 52.4 months for those with CDK5 High and /or p27 High (Table [2](#T2){ref-type="table"}). Importantly, no significant overall survival difference was observed among the patients with CDK5 High and /or p27 High expression (P=0.335), suggesting the high expression of CDK5 or p27 might functionally compensate each other\'s low expression in prognosis (Fig. [3](#F3){ref-type="fig"}B).

Last, the clinicopathological parameters that were correlated with the patient survival in the univariate analysis were included in the multivariate analysis. The tumor size, vessel invasion, distant metastasis, TNM stage, depth of invasion, distant metastasis and CDK5 and p27 co-expression status were independent prognostic factors for patients with gastric cancer, whereas lymph node metastasis, tumor location, Borrmonn type and p27 expression were not (Table [3](#T3){ref-type="table"}).

Discussion
==========

In the present study on the 244 GC patient samples, low expression of CDK5 protein was detected in 93 (38.11%) samples and low expression of p27 protein was detected in 157 (64.34%) samples. Samples with simultaneous low expression of CDK5 and p27 were 69 (28.3 %). The CDK5 Low/p27 Low expression was related to sex, Lauren\'s classification and lymph node metastasis, which indicated that a decrease in both CDK5 and p27 protein expression may cause advancing disease in patients with GC. In univariate analyses, low CDK5 expression, low p27 expression and CDK5 Low/p27 Low expression were found to be closely associated with poor survival among patients with GC (Table [2](#T2){ref-type="table"}). In multivariate analysis, the combined CDK5/p27 expression turned out to be an independent prognostic predictor for GC patients (Table [3](#T3){ref-type="table"}).

Increasing evidence demonstrated uncontrolled gastric cancer cell growth is due to disruption of the G1/S and G2/M checkpoints, which involved a series of positive and negative cell-cycle regulators[@B36], [@B37]. Zhang et al. found that CDK5 could function as a cell cycle suppressor when it localized in the nucleus in neurons[@B12]. However, CDK5 has no intrinsic nuclear localization signal. Its nuclear localization relies on its binding to p27 in neurons[@B11]. We previously discovered that nuclear CDK5 suppressed GC cell proliferation and xenograft growth independent of its kinase activity, but dependent on its association with p27[@B33]. As a cyclin-dependent kinase inhibitor, p27 could negatively modulate cell cycle progression through inhibition of the G2/M phase[@B38] and its prognostic value in GC had been reported[@B39], [@B40]. But no studies have examined the prognostic roles of the combination of CDK5 and p27 in GC. In this study, we discovered that CDK5 or p27 expression were associated with patient survival, which is consistent with our previous study and other reports. When CDK5 and p27 expression are combined, not surprisingly, the CDK5 Low/p27 Low patient group displayed a shorter overall survival than other patients (Fig [3](#F3){ref-type="fig"}A). However, no significant overall survival difference was observed among the patients with CDK5 High and /or p27 High expression (Fig. [3](#F3){ref-type="fig"}B). Further analysis revealed that in patients with high CDK5 expression, the expression of p27 was no longer associated with overall survival (Log Rank test, *P*= 0.139). Similarly, in patients with high p27 expression, the expression of CDK5 was not associated with overall survival either (Log Rank test, *P*= 0.475). Taken together, our data suggested that the tumor suppressive functions of CDK5 and p27 were closely related. The high expression of one may compensate for the loss or down regulation of another. Thus the co-expression profile of CDK5 and p27 as a prognostic marker will probably provide more accurate prediction in clinical practice.

We also found that the CDK5 Low/p27 Low expression was associated with lymph node metastasis in GC (Supplementary table [1](#SM1){ref-type="supplementary-material"}). This suggested that the identification of CDK5 Low/p27 Low expression in preoperative mucosal biopsies from GC patients might indicate the necessity for a more aggressive lymphadenectomy, albeit further studies in a larger cohort of patients are needed. In addition, considering the inferior prognosis of the CDK5 Low/p27 Low patients, more frequent follow-ups are probably needed for these patients after surgery.

In summary, co-expression of CDK5 and p27 is an independent prognostic factor for overall survival in patients with gastric cancer. Immunohistochemical analysis of CDK5 and p27 protein expression on preoperative biopsies and cancer tissues after surgery may aid in stratifying patient treatment algorithms and predicting GC patient outcome.

Supplementary Material {#SM0}
======================
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Click here for additional data file.
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![**Immunohistochemical staining for CDK5 and p27 expression in gastric cancerous tissue and the criteria for immunohistochemistry scoring. (A)**Intensity score for CDK5 expression in gastric cancer tissue. a1 to a4: no staining (score 0), weak staining (score 1), moderate staining (score 2) and strong staining (score 3). The protein expression was considered low if the score was 1 or less and high if it was 2 or more. Scale bar = 100μm. **(B)** Distribution and intensity score for p27 expression in gastric cancer tissue. b1 to b4 (distribution score): ≤ 5% positive cells (score 0), 6% to 25% positive cells (score 1), 26% to 50% positive cells (score 2) and ≥ 51% positive cells (score 3). Scale bar = 100μm. b5 to b8 (intensity score): no staining (score 0), weak staining (score 1), moderate staining (score 2) and strong staining (score 3). The protein expression was considered low if the total score (distribution score + intensity score) was 3 or less and high if it was 4 or more. Scale bar = 50μm.](jcav07p1049g001){#F1}

![Kaplan-Meier analysis of the correlation between the expression of (A) CDK5 and (B) p27 and the overall survival of gastric cancer patients.](jcav07p1049g002){#F2}

![**Kaplan-Meier analysis of the correlation between the combined CDK5 and p27 expression and the overall survival of gastric cancer patients.(A)** Patients with low expression of both CDK5 and p27 were compared with the rest of the patients.**(B)**Patients with CDK5 high and/or p27 high expression were subject to analysis.](jcav07p1049g003){#F3}

###### 

Relationships between CDK5 and p27 protein expressions (immunohistochemical staining) in gastric cancer tissues and various clinicopathological variables.

  variables                        Total   CDK5 expression         p27 expression                                        
  -------------------------------- ------- ----------------- ----- ---------------- ---------- ---- ----- ---- --------- ----------
  **Gender**                                                                                                             
  Male                             180     62                118   3.919            0.034\*         108   72   5.645     0.012\*
  Female                           64      31                33                     49         15                        
  **Age at surgery(yeas)**                                                                                               
  ≤60                              124     48                76    0.038            0.475           78    46   0.228     0.366
  \>60                             120     45                75                     79         41                        
  **Size of primary tumor (cm)**                                                                                         
  ≤5                               100     36                64    0.321            0.333           58    42   2.973     0.103
  \>5                              144     57                87                     99         45                        
  **Location of primary tumor**                                                                                          
  Lower 1/3                        57      22                35    1.541            0.673           35    22   1\. 051   0.789
  Middle 1/3                       61      22                39                     42         19                        
  Upper 1/3                        104     38                66                     65         39                        
  More than 1/3                    22      11                11                     15         7                         
  **Borrmann type**                                                                                                      
  early stage                      10      5                 5     0.679            0.712           3     7    8.416     0.150
  I+ II type                       90      33                57                     53         37                        
  III+IV type                      144     55                89                     101        43                        
  **Degree of differentiation**                                                                                          
  Well/moderate                    96      30                66    3.162            0.810           51    45   8.683     0.003\*
  Poor and not                     148     63                85                     106        42                        
  **Lauren\'s classification**                                                                                           
  Intestinal type                  196     67                129   6.528            0.013\*         124   72   0.506     0.507
  Diffuse type                     48      26                22                     33         15                        
  **Histological type**                                                                                                  
  Papillary                        7       3                 4     7.011            0.720           4     3    1.768     0.622
  Tubular                          189     64                125                    120        69                        
  Mucinous                         20      10                10                     12         8                         
  Signet-ring cell                 28      16                12                     21         7                         
  **Depth of invasion**                                                                                                  
  T1                               41      16                25    2.082            0.556           22    19   5.793     0.122
  T2                               27      8                 19                     16         11                        
  T3                               62      21                41                     37         25                        
  T4                               114     48                66                     82         32                        
  **Lymph node metastasis**                                                                                              
  N0                               64      24                40    4.253            0.235           33    31   17.033    0.001\*
  N1                               42      12                30                     20         22                        
  N2                               43      14                29                     33         10                        
  N3                               95      43                52                     71         24                        
  **TNM stage**                                                                                                          
  I                                45      16                29    0.859            0.835           25    19   12.055    0.007\*
  II                               55      19                36                     25         26                        
  III                              126     50                76                     87         31                        
  IV                               18      8                 10                     20         11                        
  **Vessel invasion**                                                                                                    
  Negative                         234     90                144                    0.746^a^        153   81             0.174^a^
  Positive                         10      3                 7                      4          6                         
  **Distant metastasis**                                                                                                 
  Negative                         226     85                141                    0.618^a^        148   81             1.000^a^
  Positive                         18      8                 10                     12         6                         

\**P*\<0.05 statistical significance; ^a^: Fisher exact test.

###### 

Univariate analysis of the correlation between clinicopathological parameters and survival of patients with gastric cancer

  Clinicopathological Parameters   Cumulative Survival Rates, %   Mean Survival Time, mo   Log-Rank Test   *P*      
  -------------------------------- ------------------------------ ------------------------ --------------- -------- ---------
  **Gender**                                                                                                        
  Male                             56.5                           49.2                     49.038          0.194    0.659
  Female                           65.6                           48.4                     49.075                   
  **Age at surgery(years)**                                                                                         
  ≤60                              60.5                           48.2                     49.394          0.007    0.935
  \>60                             55.5                           47.9                     49.285                   
  **Size of primary tumor (cm)**                                                                                    
  ≤5                               84.9                           73.7                     66.455          43.920   0.000\*
  \>5                              41.0                           30.5                     37.544                   
  **Location of primary tumor**                                                                                     
  Lower 1/3                        50.9                           38.0                     43.856          28.555   0.000\*
  Middle 1/3                       42.6                           34.4                     39.869                   
  Upper 1/3                        76.8                           67.1                     61.639                   
  More than 1/3                    31.8                           22.7                     30.500                   
  **Borrmann type**                                                                                                 
  early stage                      90.0                           90.0                     72.186          41.538   0.000\*
  I+ II type                       82.1                           71.8                     64.855                   
  III+IV type                      41.0                           30.5                     38.119                   
  **Degree of differentiation**                                                                                     
  Well/moderate                    70.8                           60.3                     57.397          8.872    0.003\*
  Poor and not                     51.1                           40.2                     44.104                   
  **Lauren\'s classification**                                                                                      
  Intestinal type                  57.1                           47.4                     48.491          0.389    0.533
  Diffuse type                     66.1                           50.7                     52.764                   
  **Histological type**                                                                                             
  Papillary                        57.1                           57.1                     50.857          1.139    0.768
  Tubular                          56.1                           48.7                     48.362                   
  Mucinous                         75.0                           53.6                     53.850                   
  Signet-ring cell                 59.4                           48.3                     50.384                   
  **Depth of invasion**                                                                                             
  T1                               97.6                           95.1                     78.026          63.910   0.000\*
  T2                               88.9                           74.1                     67.889                   
  T3                               59.2                           46.0                     48.764                   
  T4                               37.7                           28.1                     34.532                   
  **Lymph node metastasis**                                                                                         
  N0                               89.1                           81.1                     70.069          60.383   0.000\*
  N1                               68.5                           68.5                     60.550                   
  N2                               58.1                           34.9                     43.674                   
  N3                               34.7                           23.1                     32.733                   
  **TNM stage**                                                                                                     
  I                                97.7                           95.4                     77.884          75.213   0.000\*
  II                               80.1                           64.1                     62.812                   
  III                              44.1                           31.3                     39.543                   
  IV                               25.8                           16.1                     23.849                   
  **Vessel invasion**                                                                                               
  Negative                         59.7                           49.3                     50.412          8.268    0.004\*
  Positive                         20.0                           20.0                     23.400                   
  **Distant metastasis**                                                                                            
  Negative                         60.5                           50.6                     51.444          20.096   0.000\*
  Positive                         27.8                           16.7                     22.518                   
  **CDK5 expression**                                                                                               
  Low                              50.5                           40.6                     40.000          5.373    0.020\*
  High                             62.7                           52.7                     75.000                   
  **p27 expression**                                                                                                
  Low                              53.3                           42.2                     45.796          5.953    0.015\*
  High                             66.7                           58.6                     55.718                   
  **CDK5/p27 expression**                                                                                           
  CDK5 Low /p27 Low                46.4                           37.3                     40.323          10.291   0.016\*
  CDK5 High/p27 Low                58.8                           46.1                     49.153                   
  CDK5 Low /p27 High               62.5                           50.0                     51.500                   
  CDK5 High/p27 High               68.3                           61.9                     57.343                   
  **CDK5/p27 expression**                                                                                           
  CDK5 Low /p27 Low                46.4                           37.3                     40.323          8.352    0.004\*
  CDK5 high and/or p27 high        62.7                           52.3                     52.435                   

\**P*\<0.05: statistical significance.

###### 

Multivariate analysis of the correlation between clinicopathological parameters and survival time of patients with gastric cancer

  Covariates                                                   Coefficient   Standard Error   HR      95% CI for HR   *P*
  ------------------------------------------------------------ ------------- ---------------- ------- --------------- ---------
  **Tumor location** (cardia vs. others)                       N.A.          N.A.             N.A.    N.A.            N.A.
  **Tumor size** (≥5 vs.*\<*5 cm)                              0.466         0.231            1.593   1.013---2.504   0.044\*
  **Lymph node metastasis** (positive vs. negative)            N.A.          N.A.             N.A.    N.A.            N.A.
  **Vessel invasion** (positive vs. negative)                  0.765         0.369            2.148   1.042---4.431   0.038\*
  **Distant metastasis** (positive vs. negative)               0.715         0.281            2.044   1.179---3.543   0.011\*
  **Depth of invasion** (T3,T4 vs. T1,T2)                      1.047         0.385            2.849   1.338---6.064   0.007\*
  **TNM stage** (stage III and IV vs. I and II)                0.619         0.284            1.856   1.063---3.241   0.030\*
  **CDK5 and p27 expression** (low/low vs. high and/or high)   0.395         0.183            1.485   1.037---2.127   0.031\*
  **Borrmann type** (type early,I,II vs. III,IV)               N.A.          N.A.             N.A.    N.A.            N.A.

HR: hazard ratio; CI: confidence interval; \**P*\<0.05, statistical significance: N.A.: not available
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